2[2]Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol,2001,38(Suppl 2): S3-S6.
3[4]Park SJ, Lee J J, Vanhoutte PM. Endothelin-1 releases endotheliumn-derived endoperoxides and thromboxane A2 in porcine coronary arteries with regenerated endothelium. Zhongguo Yao Li Xue Bao.1999,20: 872-878.
4[5]Zhou MS, Nishida Y, Chen QH, et al. Endothelium-derived contracting factor in carotid artery of hypertensive Dahl rats. Hypertension, 1999, 34: 39-43.
5[6]Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol, 1999,31: 39-49.
6[7]Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002,296:539-541.
7[8]Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation, 2002,105: 2083-2091.
8[9]Gaddam V. Ace inhibitors in cardiovascular diseases. J Ark Med Soc,2002,98: 328-329.
9[10]Williams D, Kim KS, Adams-Campbell LL. Survival benefit from calcium channel blockers in elderly blacks following acute myocardial infarction. Ethn Dis,2002,12: 229-233.
